Buy Travoprost Online

Travoprost, sold under the brand name Travatan among others.


Active substance: Travoprost
U.S. Brand: Travatan
Indian Brand: Lupitros
Mfd by:
Strength: 0.004%
Form release: 3ml bottle
Shipping time: 7 – 21 days
Best price: 12.00 USD
Order: through request form


DescriptionHow to take?Common Side EffectsLatest New'sPhoto's

Travoprost, is medications used to treat high pressure inside the eye including glaucoma and ocular hypertension (a condition which causes increased pressure in the eye). Travoprost is in a class of medications called prostaglandin analogs. It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye.

Specifically it is used for open angle glaucoma when other agents are not sufficient. It is used as an eye drop. Effects generally occur within 2 hours. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

To instill the eye drops, follow these steps:

  1. Wash your hands thoroughly with soap and water.
  2. Check the dropper tip to make sure that it is not chipped or cracked.
  3. Avoid touching the dropper tip against your eye or anything else; eye drops and droppers must be kept clean.
  4. While tilting your head back, pull down the lower lid of your eye with your index finger to form a pocket.
  5. Hold the dropper (tip down) with the other hand, as close to the eye as possible without touching it.
  6. Brace the remaining fingers of that hand against your face.
  7. While looking up, gently squeeze the dropper so that a single drop falls into the pocket made by the lower eyelid. Remove your index finger from the lower eyelid.
  8. Close your eye for 2 to 3 minutes and tip your head down as though looking at the floor. Try not to blink or squeeze your eyelids.
  9. Place a finger on the tear duct and apply gentle pressure.
  10. Wipe any excess liquid from your face with a tissue.
  11. If you are to use more than one drop in the same eye, wait at least 5 minutes before instilling the next drop.
  12. Replace and tighten the cap on the dropper bottle. Do not wipe or rinse the dropper tip.
  13. Wash your hands to remove any medication.
  • eye pain or irritation
  • blurred vision
  • dry eyes
  • eye tearing
  • headache

Travoprost eye drops may change the color of your eye (to brown) and darken the skin around the eye. It may also cause your eyelashes to grow longer and thicker and darken in color. These changes usually occur slowly, but they may be permanent. If you use travoprost eye drops in only one eye, you should know that there may be a difference between your eyes after using travoprost eye drops. Call your doctor if you notice these changes.

Ocular Therapeutix still has an eye on approval despite trial failure

Ocular Therapeutix gave itself a low bar to clear in the latest phase III study of OTX-TP, pitting the glaucoma project against placebo rather than an active comparator – but even that was not low enough. The trial failed to show a decrease in intraocular pressure with OTX-TP, an eye insert that delivers travoprost, versus placebo, across the 12-week study. Despite the failure, Ocular still hopes the project has a future, highlighting an analysis of intraocular pressure at individual timepoints that it said showed a significant benefit with OTX-TP on eight of nine occasions. Still, as the primary endpoint was not hit, these findings can only be considered exploratory. And OTX-TP’s effect appeared to wane over time, raising questions about the company’s sustained delivery approach. Ocular will take the latest data to the FDA but even if the agency decides to be lenient, OTX-TP will struggle to find a place in the market – the project previously failed to beat an active comparator, generic timolol. Investors, who had hoped OTX-TP would fare better against placebo, sent Ocular’s stock down 17% in premarket trading today. Today’s failure might also bode ill for Ocular’s next project, OTX-TIC, a bioresorbable travoprost implant that is in phase I.

Ocular Therapeutix’s clinical-stage pipeline
Project Description Indication Status
OTX-TP Travoprost insert Glaucoma and ocular hypertension Failed phase III
OTX-TIC Travoprost implant Glaucoma and ocular hypertension Phase I
OTX-TKI Tyrosine kinase inhibitor implant Wet AMD, DME, RVO Phase I
AMD: Age-related macular degeneration, DME: Diabetic macular edema, RVO: Retinal vein occlusion. Source: EvaluatePharma, company website.
Monday Pharmaceutical Mystery: May 13

JK is a male, age 62 years, in good health. He recently started to take travoprost (Travatan Z, Alcon) 0.004% ophthalmic solution for glaucoma, 1 drop in each eye every evening. JK takes a store brand multivitamin daily, and no other maintenance prescription medications.

While picking up his supply of OTC vitamins, JK asks you if the multivitamins can cause stomach issues. Upon further discussion with the patient, he tells you that he has been experiencing heartburn, nausea, and constipation. There have been no other changes in his diet or routine, and he has been taking this particular vitamin for at least 10 years.
Mystery: What is causing JK to have gastrointestinal issues, despite no other change in medications, diet, or routine?

Solution: Travoprost has been reported to cause dyspepsia or gastrointestinal disorder in 1% to 5% of patients in clinical studies. Other uncommon nonocular side effects of travoprost include allergy, angina, anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold/flu syndrome, depression, headache, increased cholesterol, hypertension or hypotension, infection, pain, prostate disorder, sinusitis, and urinary incontinence/urinary tract infections.1

A JAMA Ophthalmology article mentions that prostaglandin analogues, such as travoprost, are the first choice in glaucoma treatment.2They work by increasing the outflow of intraocular fluid from the eye and lowering the intraocular pressure. One reason for the popularity of prostaglandin analogues is because of the limited systemic adverse effects.

Although the Travatan package insert lists the GI side effects mentioned above,1 latanoprost (Xalatan, Pfizer), bimatoprost (Lumigan, Allergan), and tafluprost (Zioptan, Akorn), also in the prostaglandin analogue class, do not list GI side effects. However, a few reported case studies showed that patients who had used latanoprost experienced GI effects,2 therefore, any patient who mentions GI upset and is taking a prostaglandin analogue should be evaluated for a correlation between the 2.

JK should speak to his ophthalmologist immediately about changing his glaucoma medication, if possible.

References

  1. Travatan Z Package Insert:  https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/travatan_z.pdf Accessed May 10, 2019
  2. Papachristou G, Ritch R, Liebmann J. JAMA Ophthalmology: Small Case Series: Gastrointestinal Adverse Effects of Prostaglandin Analogues.  Arch Ophthalmol. 2008;126(5):732-733. doi:10.1001/archopht.126.5.732 https://jamanetwork.com/journals/jamaophthalmology/fullarticle/420543Accessed May 10, 2019

Author, Karen Berger, PharmD

Karen Berger, PharmD, graduated from the University of Pittsburgh School of Pharmacy in 2001. She has worked in community pharmacies for over 17 years as a Pharmacist in Charge, staff, and floater pharmacist for a large chain. Currently, she is a pharmacist at an independent pharmacy in Northern NJ. She can be reached at karenmichelleberger@gmail.com

PhIII setback mars Ocular's glaucoma drug/device, though company remains 'encouraged' by data breakdown

Ocular Therapeutix’s latest drug/device — for glaucoma — has flopped in its Phase III study, failing the primary endpoint to significantly reduce intraocular pressure versus placebo.

The treatment, OTX-TP, is an intracanalicular insert designed to deliver a formulation of the drug travoprost with an effect up to 90 days, which Ocular says can solve the adherence issues seen with daily eye drop regimens that patients are typically prescribed.

Michael Goldstein

Investigators tracked the change in IOP from baseline in 554 patients in the study over several months, taking measurements at nine time points: 8 am, 10 am and 4 pm on one day at 2, 6 and 12 weeks following insertion. The first six sessions, the company says, were just fine — recording statistically significant reductions of IOP with p-values as low as 0.001 — but the seventh threw them off.

In fact, as they lay out in a table, that’s the only time point where OTX-TP did not achieve a statistically significant reduction of IOP compared to placebo.

“We are encouraged by the results of this trial which shows OTX-TP’s ability to lower IOP out to 12 weeks with a single insert using this novel dosage form,” said chief medical officer Michael Goldstein, adding that his team will now take the data to the FDA to determine next steps.

Ocular’s relationship with the FDA, though, has not always been smooth. Its first drug/device eye treatment, Dextenza, was rejected twice before nabbing an approval, forcing a restructuring that claimed a fifth of its staff. The company finally managed to sort out the manufacturing issue and began marketing the therapy for post-surgical pain late last year.

Some investors aren’t sticking around. Shares $OCUL are still down 12% (to $3.37) in pre-market trading, following the announcement at Monday close.

AUTHOR & ASSOCIATE EDITOR: Amber Tong
amber@endpointsnews.com

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Travoprost eye drops
Average rating:  
 0 reviews